Christophe Piot

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1195556/christophe-piot-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75 papers	6,255 citations	27 h-index	76 g-index
76 ext. papers	7,379 ext. citations	9.7 avg, IF	4.57 L-index

#	Paper	IF	Citations
75	PPARγ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia-reperfusion injury.. *Stem Cell Research and Therapy*, **2022**, 13, 167	8.3	
74	PPARγ Is Required for Mesenchymal Stem Cell Cardioprotective Effects Independently of Their Anti-inflammatory Properties in Myocardial Ischemia-Reperfusion Injury. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 681002	5.4	1
73	Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice. *Medicine (United States)*, **2020**, 99, e19119	1.8	2
72	Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study. *JACC: Cardiovascular Interventions*, **2020**, 13, 621-630	5	16
71	Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes. *PLoS ONE*, **2020**, 15, e0226606	3.7	2
70	A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. *EuroIntervention*, **2020**, 16, e328-e334	3.1	8
69	Anti-apoptotic peptide for long term cardioprotection in a mouse model of myocardial ischemia-reperfusion injury. *Scientific Reports*, **2020**, 10, 18116	4.9	4
68	A novel therapeutic peptide targeting myocardial reperfusion injury. *Cardiovascular Research*, **2020**, 116, 633-644	9.9	7
67	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. *European Heart Journal: Acute Cardiovascular Care*, **2020**, 9, 788-801	4.3	1
66	Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation. *American Journal of Cardiology*, **2019**, 124, 90-97	3	8
65	Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. *European Journal of Heart Failure*, **2019**, 21, 1619-1627	12.3	78
64	Effect and Safety of Morphine Use in Acute Anterior ST-Segment Elevation Myocardial Infarction. *Journal of the American Heart Association*, **2018**, 7,	6	31
63	A consensus statement on lipid management after acute coronary syndrome. *European Heart Journal: Acute Cardiovascular Care*, **2018**, 7, 532-543	4.3	13
62	Assessment of the area at risk after acute myocardial infarction using 123I-MIBG SPECT: Comparison with the angiographic APPROACH-score. *Journal of Nuclear Cardiology*, **2018**, 25, 572-580	2.1	11
61	Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *New England Journal of Medicine*, **2018**, 379, 2297-2306	59.2	739
60	Editors's Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. *European Heart Journal: Acute Cardiovascular Care*, **2017**, 6, 262-271	4.3	9
59	Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice. *Scientific Reports*, **2017**, 7, 14701	4.9	13

58	Cardiac mGluR1 metabotropic receptors in cardioprotection. *Cardiovascular Research*, **2017**, 113, 644-655	9.9	8
57	Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. *New England Journal of Medicine*, **2017**, 377, 1011-1021	59.2	581
56	Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. *Journal of the American College of Cardiology*, **2017**, 70, 42-55	15.1	192
55	Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. *Quality of Life Research*, **2017**, 26, 121-125	3.7	6
54	Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. *Journal of Cardiology*, **2016**, 67, 248-53	3	9
53	Predictors of ventricular remodelling in patients with reperfused acute myocardial infarction and left ventricular dysfunction candidates for bone marrow cell therapy: insights from the BONAMI trial. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 740-8	8.8	3
52	close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. *International Journal of Stroke*, **2016**, 11, 724-32	6.3	9
51	Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry. *Journal of the American College of Cardiology*, **2016**, 68, 1637-1647	15.1	82
50	Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial). *American Heart Journal*, **2015**, 169, 758-766.e6	4.9	22
49	Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. *Circulation: Cardiovascular Interventions*, **2015**, 8, e001441	6	137
48	Cyclosporine before PCI in Patients with Acute Myocardial Infarction. *New England Journal of Medicine*, **2015**, 373, 1021-31	59.2	412
47	Influence of cardiovascular risk factors on infarct size and interaction with mechanical ischaemic postconditioning in ST-elevation myocardial infarction. *Open Heart*, **2015**, 2, e000175	3	7
46	The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. *Basic Research in Cardiology*, **2014**, 109, 400	11.8	96
45	Everolimus-eluting stent for the treatment of bare metal in-stent restenosis: clinical and angiographic outcomes at nine-month follow-up of XERES (Xience Evaluation in bare metal stent REStenosis) trial. *EuroIntervention*, **2014**, 10, 700-8	3.1	5
44	What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. *Cardiovascular Drugs and Therapy*, **2013**, 27, 315-31	3.9	18
43	Postconditioning attenuates no-reflow in STEMI patients. *Basic Research in Cardiology*, **2013**, 108, 383	11.8	65
42	Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial. *Stem Cell Research and Therapy*, **2013**, 4, 152	8.3	15
41	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. *International Journal of Cardiology*, **2013**, 168, 4244-8	3.2	12

40	Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial. *Archives of Cardiovascular Diseases*, **2013**, 106, 135-45	2.7	10
39	Pharmacological approaches to reperfusion therapy. *Cardiovascular Research*, **2012**, 94, 246-52	9.9	18
38	Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology*, **2012**, 59, 2175-81	15.1	171
37	Delayed postconditioning: not too late?. *Trends in Cardiovascular Medicine*, **2012**, 22, 173-9	6.9	8
36	Could heart rate play a role in pericardial inflammation?. *Medical Hypotheses*, **2012**, 79, 512-5	3.8	13
35	Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. *Basic Research in Cardiology*, **2012**, 107, 275	11.8	57
34	Down-regulation of the transcription factor ZAC1 upon pre- and postconditioning protects against I/R injury in the mouse myocardium. *Cardiovascular Research*, **2012**, 94, 351-8	9.9	9
33	Translating Cardioprotective Strategies into Clinical Settings **2012**, 87-99		
32	Infarct size reduction in patients with STEMI: why we can do it!. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2011**, 16, 298-303	2.6	6
31	Delayed postconditioning in the mouse heart in vivo. *Circulation*, **2011**, 124, 1330-6	16.7	63
30	Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. *European Heart Journal*, **2011**, 32, 1748-57	9.5	132
29	Postconditioning in acute myocardial infarction patients. *Antioxidants and Redox Signaling*, **2011**, 14, 811-20	8.4	17
28	Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. *Journal of the American College of Cardiology*, **2010**, 55, 1200-1205	15.1	155
27	Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement. *Journal of the American College of Cardiology*, **2010**, 56, 1024-31	15.1	19
26	Cardioprotection in the clinical setting. *Cardiovascular Drugs and Therapy*, **2010**, 24, 281-7	3.9	12
25	Aorta thrombosis diagnosed due to acute myocardial infarct. *Journal of Cardiology Cases*, **2010**, 2, e139-e140		
24	Inhibition of mitochondrial permeability transition pore opening: translation to patients. *Cardiovascular Research*, **2009**, 83, 226-33	9.9	63
23	Effect of cyclosporine on reperfusion injury in acute myocardial infarction. *New England Journal of Medicine*, **2008**, 359, 473-81	59.2	1026

22	Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. *Diabetes Care*, **2008**, 31, 593-5	14.6	10
21	Long-term benefit of postconditioning. *Circulation*, **2008**, 117, 1037-44	16.7	347
20	Epstein Barr virus (EBV) and acute myopericarditis in an immunocompetent patient: first demonstrated case and discussion. *Internal Medicine*, **2008**, 47, 627-9	1.1	25
19	Repeated high doses of clopidogrel in 2 cases of pharmacological resistance. *Circulation Journal*, **2008**, 72, 2098-100	2.9	1
18	Recent malignant dyspnea. *Internal Medicine*, **2008**, 47, 427-9	1.1	1
17	Likely tuberculous myocarditis mimicking an acute coronary syndrome. *Internal Medicine*, **2008**, 47, 1699-701	1.1	7
16	Postconditioning in man. *Heart Failure Reviews*, **2007**, 12, 245-8	5	27
15	Myocardial expression of a dominant-negative form of Daxx decreases infarct size and attenuates apoptosis in an in vivo mouse model of ischemia/reperfusion injury. *Circulation*, **2007**, 116, 2709-17	16.7	27
14	Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. *Diabetes Care*, **2007**, 30, 2934-9	14.6	57
13	Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. *American Heart Journal*, **2006**, 151, 690-8	4.9	40
12	Morphine mimics the antiapoptotic effect of preconditioning via an Ins(1,4,5)P3 signaling pathway in rat ventricular myocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H83-8	5.2	24
11	Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. *Diabetes Care*, **2005**, 28, 2176-80	14.6	75
10	Postconditioning the human heart. *Circulation*, **2005**, 112, 2143-8	16.7	831
9	Risk factors for silent myocardial ischemia in high-risk type 1 diabetic patients. *Diabetes Care*, **2004**, 27, 1745-7	14.6	9
8	Inflammatory parameters are independent predictors of severe epicardial coronary stenosis in asymptomatic diabetic patients with silent myocardial ischemia. *Diabetes Care*, **2003**, 26, 545-6	14.6	6
7	Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. *European Journal of Heart Failure*, **2003**, 5, 481-8	12.3	49
6	QRS and cycle length alternans during paroxysmal supraventricular tachycardia: what is the mechanism?. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 92-3	2.7	29
5	Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 277, H2458-69	5.2	23

4	Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly(ADP-ribose) polymerase in rat hearts in vivo. *Cardiovascular Research*, **1999**, 44, 536-42	9.9	46
3	A "dysautonomic" head-up tilt test pattern in elderly patients with neurocardiogenic syncope. *PACE - Pacing and Clinical Electrophysiology*, **1999**, 22, 1004-12	1.6	6
2	Ischemic preconditioning decreases apoptosis in rat hearts in vivo. *Circulation*, **1997**, 96, 1598-604	16.7	125
1	High frequency-induced upregulation of human cardiac calcium currents. *Circulation*, **1996**, 93, 120-8	16.7	89